These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24199650)

  • 1. ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.
    Kołaczkowski M; Mierzejewski P; Bieńkowski P; Wesołowska A; Newman-Tancredi A
    Br J Pharmacol; 2014 Feb; 171(4):973-84. PubMed ID: 24199650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
    Partyka A; Wasik A; Jastrzębska-Więsek M; Mierzejewski P; Bieńkowski P; Kołaczkowski M; Wesołowska A
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):593-602. PubMed ID: 26979176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M; Marcinkowska M; Bucki A; Pawłowski M; Mitka K; Jaśkowska J; Kowalski P; Kazek G; Siwek A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
    J Med Chem; 2014 Jun; 57(11):4543-57. PubMed ID: 24805037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
    Bucki A; Marcinkowska M; Śniecikowska J; Zagórska A; Jamrozik M; Pawłowski M; Głuch-Lutwin M; Siwek A; Jakubczyk M; Pytka K; Jastrzębska-Więsek M; Partyka A; Wesołowska A; Mierzejewski P; Kołaczkowski M
    Eur J Med Chem; 2020 Apr; 191():112149. PubMed ID: 32105980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antagonists of 5-HT
    Partyka A; Jastrzębska-Więsek M; Antkiewicz-Michaluk L; Michaluk J; Wąsik A; Canale V; Zajdel P; Kołaczkowski M; Wesołowska A
    Behav Brain Res; 2019 Feb; 359():9-16. PubMed ID: 30312638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia.
    Kołaczkowski M; Mierzejewski P; Bienkowski P; Wesołowska A; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):545-57. PubMed ID: 24599316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A
    Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
    Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone.
    Horisawa T; Nishikawa H; Toma S; Ikeda A; Horiguchi M; Ono M; Ishiyama T; Taiji M
    Behav Brain Res; 2013 May; 244():66-9. PubMed ID: 23376699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the halogen bonding on D
    Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
    Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.
    Yamazaki M; Harada K; Yamamoto N; Yarimizu J; Okabe M; Shimada T; Ni K; Matsuoka N
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1698-708. PubMed ID: 25108314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.
    Marcos B; Chuang TT; Gil-Bea FJ; Ramirez MJ
    Br J Pharmacol; 2008 Oct; 155(3):434-40. PubMed ID: 18622410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine.
    Brea J; Castro M; Loza MI; Masaguer CF; Raviña E; Dezi C; Pastor M; Sanz F; Cabrero-Castel A; Galán-Rodríguez B; Fernández-Espejo E; Maldonado R; Robledo P
    Neuropharmacology; 2006 Aug; 51(2):251-62. PubMed ID: 16697427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of antipsychotics with 5-HT(2C) receptor affinity in behavioral assays selective for 5-HT(2C) receptor antagonist properties of compounds.
    Prinssen EP; Koek W; Kleven MS
    Eur J Pharmacol; 2000 Jan; 388(1):57-67. PubMed ID: 10657547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.